We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Inovio Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$6.92 – a decrease of 3.89% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$5.81 - US$19 |
|---|---|
| 50-day moving average | US$7.1924 |
| 200-day moving average | US$8.5005 |
| Target price | US$13 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $6.92
| 1 week (2021-11-19) | -5.85% |
|---|---|
| 1 month (2021-10-26) | 1.17% |
| 3 months (2021-08-26) | -20.46% |
| 6 months (2021-05-26) | -6.11% |
| 1 year (2020-11-25) | -33.40% |
|---|---|
| 2 years (2019-11-26) | 174.60% |
| 3 years (2018-11-26) | 30.57% |
| 5 years (2016-11-25) | -9.90% |
| Revenue TTM | US$6.5 million |
|---|---|
| Gross profit TTM | US$-86,834,216 |
| Return on assets TTM | -28.9% |
| Return on equity TTM | -56.86% |
| Profit margin | 0% |
| Book value | 2.156 |
| Market capitalisation | US$1.5 billion |
TTM: trailing 12 months
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 6 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as US$5.81 up to US$19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.5849. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquart
Get up to 58% off on robot cleaners to barrels and cordless sticks to all things Dyson during the Black Friday sales.
These are the best Black Friday deals for Nintendo Switch, including up to 59% off bestselling Switch games.
The best Black Friday 2021 discounts include over $1,000 off 75-inch and 85-inch smart TVs from Samsung and Hisense.
Black Friday bargains include discounts on the Apple Watch Series 3 and Apple Watch accessories.
Get the Nintendo Switch bundled with Mario Kart 8 Deluxe and a 3-month Nintendo Switch Online subscription for $369 - save $160!
The biggest discounts include $200 off the Apple AirPods Max, 40% off the Beats Solo3, 38% off Jabra Elite 75t Earbuds and 56% off Sennheiser HD 400s.
Save over $1000 on gaming laptops during Black Friday 2021 from Dell, MSI, Lenovo, OMEN and Alienware and more.
